European/International FMD Registry and Initiative

NCT ID: NCT04804683

Last Updated: 2022-05-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 5000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-11
• Study Completion Date: 2031-03-10

Brief Summary

The main objectives of FEIRI are:

(i) To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and/or ethnic origin

(ii) To evaluate the incidence and predictors of novel FMD lesions and complications

(iii) To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and/or aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)

(iv) To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases

Participation to the FEIRI study implies:

(i) Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).

(ii) Optional participation to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.

Participants will be enrolled in centres from over 20 countries in Europe and beyond.

Detailed Description

Fibromuscular dysplasia (FMD) is an idiopathic, segmental, nonatherosclerotic, and noninflammatory disease of the musculature of arterial walls, leading to stenosis of small- and medium-sized arteries. FMD can be classified in multifocal FMD, characterized by alternation of stenosis and dilations ("string-of-beads") and focal FMD, corresponding to a solitary narrowing. While for long FMD was considered as a rare cause of renovascular disease mostly affecting young women, during the last decades, joint international efforts have led to a thorough reappraisal of the disease. In summary, (i) FMD is no more considered as a truly rare disease; (ii) FMD may be also diagnosed in men (10-20%) and at all ages; (iii) beyond arterial stenosis, FMD is often associated with dissections, aneurysms and arterial tortuosity; (iv) FMD is not restricted to renal arteries and often affects two or more arterial beds; (iv) multifocal FMD lesions are frequent in patients with Spontaneous Coronary Artery Dissection (SCAD).

Despite traditional views on the role of female hormones, mechanical factors and smoking, the pathophysiology of FMD remains largely unknown. In the last decade, research has been focused on genetic dissection of the disease and identification of biomarkers. Recent advances include: (i) identification of an association between FMD and an intronic variant of the Phosphatase and actin regulator 1 (PHACTR1) gene; (ii) identification of rare mutations in several genes such as Prostaglandin I2 Receptor (PTGIR) and Collagen type V alpha 1 chain (COL5A1) genes; (iii) documentation of mild Connective-Tissue Disease-like features and increased levels of Transforming Growth Factor-beta in patients with FMD; (iv) identification of a tentative proteo-genomic signature of the disease. All elements are thus in place to further dissect the pathophysiology of FMD and related diseases, refine clinical characterization, identify predictors of complications and improve screening, management and follow-up.

Unravelling the clinical characteristics, genetic and molecular basis of FMD nevertheless requires large numbers of well characterized patients. In order to address these challenges and generate new evidence pertaining to FMD and associated diseases, we aimed to create an overarching resource and study named "the European/International FMD Registry and Initiative" (acronym: FEIRI).

The objectives of FEIRI are:

To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and/or ethnic origin

To identify environmental/ hormonal factors and exposures associated with the onset and progression of FMD

To evaluate the incidence and predictors of novel FMD lesions and complications

To provide evidence-based algorithms for the diagnosis and optimal management and follow-up of patients with FMD

To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and/or aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)

To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases

Participation to the FEIRI study implies:

Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).

Optional participation (both for centres and patients) to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.

Participants will be enrolled in centres from over 20 countries in Europe and beyond.

Conditions

Fibromuscular Dysplasia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Cohort of patients with Fibromuscular Dysplasia

Intervention consists in blood/urine sampling

Group Type: OTHER

Genetic dissection of Fibromuscular Dysplasia

Intervention Type: GENETIC

Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia

Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia

Intervention Type: OTHER

Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia

Interventions

Genetic dissection of Fibromuscular Dysplasia

Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia

Intervention Type: GENETIC

Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia

Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

(i) Patients with established FMD, i.e at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD).

(ii) Patients with Spontaneous Coronary Artery Dissection (SCAD) in whom at least one lesion of multifocal FMD (string-of beads) in extra-coronary arteries has been identified ("SCAD-FMD").

(iii) Patients with so-called "atypical FMD" or "FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms < 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy.

Exclusion Criteria

Diagnosis based only on ultrasound (need for computed tomographic angiography , magnetic resonance angiography or catheter-based angiography to confirm the diagnosis)

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role: lead

Responsible Party

PERSU Alexandre

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alexandre Persu, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Locations

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status: RECRUITING

Countries

Belgium

Central Contacts

Alexandre Persu, MD-PhD

Role: CONTACT

alexandre.persu@uclouvain.be

0032 2 764 63 06

Facility Contacts

Alexandre Persu, MD-PhD

Role: primary

alexandre.persu@uclouvain.be

0032 2 764 63 06

Other Identifiers

2015/28AOU/464

Identifier Type: -

Identifier Source: org_study_id